Kexing Biopharm (688136.SH): Marketing authorization application for pegylated human granulocyte colony-stimulating factor injection accepted

Zhitong Finance APP News, Kexing Biopharm (688136.SH) announced that recently, the company received the "Notice of Acceptance" issued by the National Medical Products Administration for the marketing authorization application of its investigational drug PEGylated human granulocyte colony-stimulating factor injection (referred to as "GB-K02"). The company's GB-K02 is indicated for reducing the incidence of infection, manifested as febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs that are associated with a clinically significant incidence of febrile neutropenia.